Banner - Collaborative Care Symposium
News
All NewsContributorsMoney Matters
Media
All VideosExpert InterviewsMedical World NewsPodcastsCase Based Roundtable SeriesCase of the QuarterEyeViewGrand RoundsInsightsRapid ReadoutViewpointsWhat’s Your WhEYE?
Conferences
Conference CoverageConference Listing
Events
More
Publications
Digital EditionEurope Ophthalmology TimesModern RetinaSupplements and Featured Publications
CME
Partners
Resources
Job BoardSponsored

Subscribe

  • News
  • Media
  • Conferences
  • Events
  • Publications
  • CME
  • Partners
  • Subscribe
  • Resources
  • AMD
  • Biosimilars
  • COVID-19
  • Cataract
    • Cataract Surgery
  • Cataract Therapeutics
  • Clinical Diagnosis
    • The Residency Report
    • iOpeners
    • NeuroOp Guru
  • Cornea
  • DME
  • Dry Eye
    • Dry Eye Awareness
  • Gene Therapy
  • Geographic Atrophy
  • IOL
    • IOL Advances
  • Imaging
  • Interventional Glaucoma
    • Glaucoma Awareness
    • Glaucoma Insights
    • Therapeutic Glaucoma
  • OCT
  • Ocular Allergy
  • Ocular Surface Disease
  • Optic Relief
  • Optometry
  • Pediatrics
  • Pharmacy
  • Practice Management
    • Indispensable
  • Presbyopia
  • Ptosis
  • Refractive
    • Refractive Surgery
  • Retina
  • Surgery
  • Technology
  • Therapeutics
  • Understanding Antibiotic Resistance
  • Workplace
Spotlight -
Retina
Advertisement

Ira Udell, MD

Advertisement

Articles by Ira Udell, MD

The sky is the limit for allergy pipeline

ByIra Udell, MD
February 18th 2021

Growing patient pool is driving clinical trial investment.

Advertisement

Latest Updated Articles

  • The sky is the limit for allergy pipeline
    The sky is the limit for allergy pipeline

    Published: February 18th 2021 | Updated:



Advertisement
Advertisement

Trending on Ophthalmology Times - Clinical Insights for Eye Specialists

1

UPDATE: STAAR postpones Alcon merger vote, Broadwood calls for removal of board members

2

Advancements in femtosecond laser technology benefit surgeons and patients

3

Research supports that iron dysregulation may drive AMD

4

ONL Therapeutics randomizes first patient in phase 2 GALAXY trial evaluating xelafaslatide

5

Bimatoprost drug pad-IOL system shows reduction in mean IOP at 24 months

  • About
  • Advertise
  • Privacy
  • Editorial Info
  • Editorial Board
  • Terms and Conditions
  • Contact Us
  • Do Not Sell My Personal Information
  • Job Board
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

609-716-7777

  • Ophthalmology Times
  • Modern Retina
  • Optometry Times
  • Ophthalmology Times Europe
EyeCare Network
Brand Logo

© 2025 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us